Work

Clinical Outcomes and Adverse Effect Management of Sotorasib in a KRAS G12C Mutated NSCLC Patient

Year: 2024

Type: article

Abstract: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, frequently driven by genetic mutations such as KRAS.This case report presents a 67-year-old female patient diagnosed with NSCLC of the right lung, harboring a KRAS G12C mutation.Initial treatment with stereotactic body radiotherapy (SBRT) and chemotherapy was poorly tolerated, leading to the administration of sotorasib, a KRAS G12C inhibitor.The patient experienced adverse effects including severe rash, diarrhea, and acid reflux, necessitating dose adjustments.This report details the clinical course, management strategies for adverse effects, and outcomes in the context of KRAS G12C-mutated NSCLC treated with sotorasib.

Source: Medical & Clinical Case Reports Journal

DOI: 10.51219/mccrj/supriya-peshin/128

Authors: Shivani Modi, Supriya Peshin, Shagun Singh, Nagaishwarya Moka

Institutions: Einstein Healthcare Network, Norton Community Hospital, Banner Health, Lincoln Memorial University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4403268508

FWCI: 0.259

Cites:

Cited by: 1

Related to: 10